SPERO THERAPEUTICS, INC. (SPRO)

Every figure this model derived for SPRO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2020-12-31
cash 50,774,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 51,584,000 AssetsCurrent 2026-06-30
current liabilities 8,428,000 LiabilitiesCurrent 2026-06-30
equity 44,204,000 StockholdersEquity 2026-06-30
ocf 19,580,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 46,997,000 Revenues 2026-06-30
sbc 3,991,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SPRO on one particular measure came for.

RatioValue
cash operating margin21.31
current ratio6.12
current ratio reported6.12
deferred revenue growth-100.0
dilution pct9.26
fcf margin41.66
growth cv1.1
operating margin12.82
owner earnings margin33.17
revenue growth-3.25
revenue growth per share-11.45
rule of 409.57
sbc pct revenue8.49

What to be careful about

What this model itself distrusts about SPRO's figures. Written by the derivation as it ran, not added afterwards.